CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Creative Medical Technology Holdings is a commercial-stage biotechnology company developing regenerative therapies in immunotherapy, endocrinology, urology, neurology and orthopedics. Its programs include AlloStem, an allogenic cell therapy platform; ImmCelz, which uses a patient’s reprogrammed immune cells; and iPScelz, an induced pluripotent stem cell program. Other products and procedures include CELZ-201 therapies for Type 1 diabetes and lower back pain, StemSpine for chronic lower back pain, OvaStem for premature ovarian failure, and CaverStem and FemCelz for sexual health conditions. The company also develops cell therapies for additional indications and offers procedures using patients’ own cells. The company makes money from sales of products and procedures and may receive payments from licensing intellectual property; CaverStem generated minimal revenues in 2023 and 2024. Its principal executive offices are in Phoenix, Arizona.
No enriched coverage for $CELZ in the last 7 days.
No SEC Form 4 filings for $CELZ in the last 30 days.
See all $CELZ insider activity →Creative Medical Technology Holdings (CELZ) presented clinical and lab findings for Ultrasome™, its cell-free regenerative medicine platform. A 30-patient study showed 65% reduction in average pain score and 52% reduction in WOMAC score over six months. No serious adverse events were reported. The company plans to publish full findings in a peer-reviewed manuscript.
Timothy Warbington, CEO of Creative Medical Technology Holdings (CELZ), disclosed a 13.7% stake in the company's common stock. The investment follows a deal where Creative Acquisition Corp., led by Warbington, received 1 million restricted shares. Warbington plans to hold the shares for investment purposes but may buy or sell more in the future. He has no current plans for board changes or mergers. Warbington also serves as Chairman and CEO of Creative Acquisition Corp.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purcha
Recent CELZ coverage spans financial news, corporate actions and market movers.
Positive early‑stage trial data may boost investor confidence in CELZ's regenerative platform.
Insider stake increase may signal confidence and could attract buying interest.
The acquisition gives CELZ control of BioDefense, potentially expanding its product pipeline and market reach.
Dilution from share increase and warrant exercise may pressure price; increased float could improve liquidity.
Patent expansion is a near-term catalyst that can sustain momentum and raise perceived IP defensibility for CELZ-101/CELZ-201 platforms.
AlphAI scores every news story that mentions CELZ with an AI model for sentiment and relevance, and aggregates insider trades from CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Creative Medical Technology Holdings (CELZ) presented clinical and lab findings for Ultrasome™, its cell-free regenerative medicine platform. A 30-patient study showed 65% reduction in average pain score and 52% reduction in WOMAC score over six months. No serious adverse events were reported. The company plans to publish full findings in a peer-reviewed manuscript.
Timothy Warbington, CEO of Creative Medical Technology Holdings (CELZ), disclosed a 13.7% stake in the company's common stock. The investment follows a deal where Creative Acquisition Corp., led by Warbington, received 1 million restricted shares. Warbington plans to hold the shares for investment purposes but may buy or sell more in the future. He has no current plans for board changes or mergers. Warbington also serves as Chairman and CEO of Creative Acquisition Corp.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 24, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) entered into a Stock Purchase Agreement (the “Purchase Agreement”) with Creative Acquisition Corp. (“CAC”), pursuant to which the Company purcha
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 28, 2026, the stockholders of Creative Medical Technology Holdings, Inc. (the “Company”) approved an amendment to the Company’s Articles of Incorporation to increase the number of author
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-4.1 2 celz_ex41.htm FORM OF INDUCEMENT WARRANT celz_ex41.htm EXHIBIT 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON
Creative Medical Technology Holdings (NASDAQ: CELZ) issued a mid-year update. It said Olastrocel (CELZ-201) has WHO-approved naming and reported positive interim 180-day ADAPT trial results; the FDA cleared an expanded cohort for patients using <90 mg/day morphine equivalents. Ultrasome™ pilot data showed a 93% primary endpoint response. The CELZ-Biodefense Atlas program advanced to nationwide AI-enabled veteran data collection.
Creative Medical Technology Holdings (CELZ) said it secured about $4.5M in gross proceeds via warrant exercises and related stock purchases. The company will exercise warrants for up to 2,790,340 shares and investors will buy 5,580,680 shares at $1.60/share, with new five-year warrants issued. Closing is expected June 30, 2026.
Creative Medical Technology Holdings (Nasdaq: CELZ) said it agreed with warrant holders to immediately exercise existing warrants for up to 2,790,340 shares at a reduced $1.60 exercise price, raising about $4.5M gross proceeds before fees. In return, it will issue new unregistered warrants for up to 5,580,680 shares at $1.60, pending shareholder approval. Closing expected June 30, 2026.
Creative Medical Technology (CELZ) said the FDA cleared an amended protocol to expand its ADAPT trial of Olastrocel (CELZ-201) for chronic lower back pain. The company will add 15 patients using <90 mg morphine equivalents/day; the new cohort is 85% enrolled and uses its AI pain-medication monitoring. Creative Medical cited positive 180-day interim results and a DSMB report of no significant adverse events, and said it is preparing for Phase 3 discussions.
